Selective serotonin reuptake inhibitor use in the treatment of the pediatric non-obsessive-compulsive disorder anxiety disorders

Laura Seidel, John T. Walkup*

*Corresponding author for this work

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

The non-OCD (obsessive-compulsive disorder) anxiety disorders in the pediatric population-separation anxiety disorder, generalized anxiety disorder, and social phobia and others-are arguably the most common psychiatric disorders in this age group. Anxiety disorders, in addition to being common, also significantly impair the affected child at home, school, and with peers. A small developing evidence base suggests the selective serotonin reuptake inhibitors (SSRIs) are the pharmacological treatment of choice for pediatric non-OCD anxiety disorders. In clinical trials, SSRIs are often very effective in reducing symptoms and improving functioning and generally well tolerated. The U.S. Food and Drug Administration's (FDA) review of the safety of antidepressants in the pediatric population suggest a small, but significant, increased relative risk for suicidality adverse events on antidepressant versus placebo. Despite the apparent increased risk, the larger magnitude of benefit of the SSRIs for pediatric non-OCD anxiety disorders compared to depression suggests the benefit/risk ratio for anxiety disorders is more favorable than that for depression. This paper will review available studies on the treatment of non-OCD childhood anxiety disorders with antidepressants, including the SSRIs, and discuss pertinent safety issues.

Original languageEnglish (US)
Pages (from-to)171-179
Number of pages9
JournalJournal of Child and Adolescent Psychopharmacology
Volume16
Issue number1-2
DOIs
StatePublished - Feb 1 2006

Fingerprint

Serotonin Uptake Inhibitors
Anxiety Disorders
Pediatrics
Antidepressive Agents
Therapeutics
Separation Anxiety
Depression
Safety
Obsessive-Compulsive Disorder
United States Food and Drug Administration
Population
Psychiatry
Age Groups
Odds Ratio
Placebos
Clinical Trials
Pharmacology

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

@article{7ed46ce3c1c44611b3d9fb32ad171a23,
title = "Selective serotonin reuptake inhibitor use in the treatment of the pediatric non-obsessive-compulsive disorder anxiety disorders",
abstract = "The non-OCD (obsessive-compulsive disorder) anxiety disorders in the pediatric population-separation anxiety disorder, generalized anxiety disorder, and social phobia and others-are arguably the most common psychiatric disorders in this age group. Anxiety disorders, in addition to being common, also significantly impair the affected child at home, school, and with peers. A small developing evidence base suggests the selective serotonin reuptake inhibitors (SSRIs) are the pharmacological treatment of choice for pediatric non-OCD anxiety disorders. In clinical trials, SSRIs are often very effective in reducing symptoms and improving functioning and generally well tolerated. The U.S. Food and Drug Administration's (FDA) review of the safety of antidepressants in the pediatric population suggest a small, but significant, increased relative risk for suicidality adverse events on antidepressant versus placebo. Despite the apparent increased risk, the larger magnitude of benefit of the SSRIs for pediatric non-OCD anxiety disorders compared to depression suggests the benefit/risk ratio for anxiety disorders is more favorable than that for depression. This paper will review available studies on the treatment of non-OCD childhood anxiety disorders with antidepressants, including the SSRIs, and discuss pertinent safety issues.",
author = "Laura Seidel and Walkup, {John T.}",
year = "2006",
month = "2",
day = "1",
doi = "10.1089/cap.2006.16.171",
language = "English (US)",
volume = "16",
pages = "171--179",
journal = "Journal of Child and Adolescent Psychopharmacology",
issn = "1044-5463",
publisher = "Mary Ann Liebert Inc.",
number = "1-2",

}

TY - JOUR

T1 - Selective serotonin reuptake inhibitor use in the treatment of the pediatric non-obsessive-compulsive disorder anxiety disorders

AU - Seidel, Laura

AU - Walkup, John T.

PY - 2006/2/1

Y1 - 2006/2/1

N2 - The non-OCD (obsessive-compulsive disorder) anxiety disorders in the pediatric population-separation anxiety disorder, generalized anxiety disorder, and social phobia and others-are arguably the most common psychiatric disorders in this age group. Anxiety disorders, in addition to being common, also significantly impair the affected child at home, school, and with peers. A small developing evidence base suggests the selective serotonin reuptake inhibitors (SSRIs) are the pharmacological treatment of choice for pediatric non-OCD anxiety disorders. In clinical trials, SSRIs are often very effective in reducing symptoms and improving functioning and generally well tolerated. The U.S. Food and Drug Administration's (FDA) review of the safety of antidepressants in the pediatric population suggest a small, but significant, increased relative risk for suicidality adverse events on antidepressant versus placebo. Despite the apparent increased risk, the larger magnitude of benefit of the SSRIs for pediatric non-OCD anxiety disorders compared to depression suggests the benefit/risk ratio for anxiety disorders is more favorable than that for depression. This paper will review available studies on the treatment of non-OCD childhood anxiety disorders with antidepressants, including the SSRIs, and discuss pertinent safety issues.

AB - The non-OCD (obsessive-compulsive disorder) anxiety disorders in the pediatric population-separation anxiety disorder, generalized anxiety disorder, and social phobia and others-are arguably the most common psychiatric disorders in this age group. Anxiety disorders, in addition to being common, also significantly impair the affected child at home, school, and with peers. A small developing evidence base suggests the selective serotonin reuptake inhibitors (SSRIs) are the pharmacological treatment of choice for pediatric non-OCD anxiety disorders. In clinical trials, SSRIs are often very effective in reducing symptoms and improving functioning and generally well tolerated. The U.S. Food and Drug Administration's (FDA) review of the safety of antidepressants in the pediatric population suggest a small, but significant, increased relative risk for suicidality adverse events on antidepressant versus placebo. Despite the apparent increased risk, the larger magnitude of benefit of the SSRIs for pediatric non-OCD anxiety disorders compared to depression suggests the benefit/risk ratio for anxiety disorders is more favorable than that for depression. This paper will review available studies on the treatment of non-OCD childhood anxiety disorders with antidepressants, including the SSRIs, and discuss pertinent safety issues.

UR - http://www.scopus.com/inward/record.url?scp=33645830064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645830064&partnerID=8YFLogxK

U2 - 10.1089/cap.2006.16.171

DO - 10.1089/cap.2006.16.171

M3 - Article

VL - 16

SP - 171

EP - 179

JO - Journal of Child and Adolescent Psychopharmacology

JF - Journal of Child and Adolescent Psychopharmacology

SN - 1044-5463

IS - 1-2

ER -